HeartBeam, Inc. (BEAT)
| Market Cap | 21.36M -63.8% |
| Revenue (ttm) | n/a |
| Net Income | -20.30M |
| EPS | -0.50 |
| Shares Out | 56.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 735,606 |
| Open | 0.3900 |
| Previous Close | 0.4037 |
| Day's Range | 0.3630 - 0.4046 |
| 52-Week Range | 0.3550 - 4.0000 |
| Beta | -0.85 |
| Analysts | Buy |
| Price Target | 3.50 (+823.24%) |
| Earnings Date | Nov 12, 2026 |
About BEAT
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart’s electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician port... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for BEAT stock is "Buy." The 12-month stock price target is $3.5, which is an increase of 823.24% from the latest price.
News
HeartBeam price target lowered to $1.25 from $2 at Maxim
Maxim lowered the firm’s price target on HeartBeam (BEAT) to $1.25 from $2 and keeps a Buy rating on the shares. The firm is adjusting its model to reflect the…
HeartBeam Earnings Call Transcript: Q3 2026
Q3 delivered major regulatory and clinical milestones for heart attack detection, while cost reductions lowered quarterly cash burn and losses. FY2026 operating cash outflow guidance is $12 million–$12.5 million, with a U.S. pivotal study targeted to begin by Q1 2027.
HeartBeam Quarterly report: Q3 2026
HeartBeam has published its Q3 2026 quarterly earnings report on November 12, 2026.
HeartBeam Earnings release: Q3 2026
HeartBeam released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
HeartBeam Slides: Q3 2026
HeartBeam has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 12, 2026.
HeartBeam reports Q3 EPS (5c) vs. (15c) last year
Cash and cash equivalents totaled $6.1 million as of September 30, 2026, compared to $4.4 million as of December 31, 2025. In August 2026, the Company entered into an at-the-market…
HeartBeam Reports Third Quarter 2026 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Third Quarter 2026 Results.
HeartBeam to Host Third Quarter 2026 Results Conference Call on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2026 Results Conference Call on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time.
HeartBeam announces results from ALIGN-ACS pilot study of HeartBeam System
HeartBeam (BEAT) announced positive results from its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack assessment. The results were presented in an oral presentation by Graham Nic...
HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to Be as Accurate as Standard 12-Lead ECG
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to be as Accurate as Standard 12-Lead ECG.
HeartBeam to present results of ALING-ACS study at TCT 2026
HeartBeam (BEAT) announced that the results of the ALIGN-ACS pilot study evaluating the HeartBeam 3D ECG technology for heart attack assessment will be presented at TCT 2026, taking place at…
HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026.
HeartBeam announces U.S. FDA accepted HeartBeat System to its TAP Pilot
HeartBeam (BEAT) announced that the U.S. Food and Drug Administration, FDA, has accepted the HeartBeam System into its Total Product Life Cycle Advisory Program, TAP, Pilot, a voluntary FDA program…
HeartBeam announces HEADSTART-ACS study completed enrollment
HeartBeam (BEAT) announced that the HEADSTART-ACS study, conducted at the National Cardiovascular Center Harapan Kita in Jakarta, Indonesia, has completed enrollment ahead of schedule. The study enrol...
HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology
SANTA CLARA, Calif.--(BUSINESS WIRE)--HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology.
HeartBeam joins European EXIT-CVD Research Consortium
HeartBeam (BEAT) is a contributing partner in the launch of the EXIT-CVD research project, co-funded by the European Union Innovative Health Initiative and industry partners. The research consortium i...
HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome.
Why These 3 Penny Stocks Are on Investors’ Radar Today
WISeSat.Space Holdings ($SAIQ), Veea Inc. ($VEEA), and HeartBeam Inc. ($BEAT) are among the penny stocks to watch on October 6, according to TipRanks’ Penny Stock Screener Tool. A penny stock typicall...
Why Is Penny Stock HeartBeam (BEAT) Up Nearly 60% Today?
HeartBeam stock was up nearly 60% on Monday thanks to an FDA update for the company’s HeartBeam System.
HeartBeam receives FDA Breakthrough Device Designation for HeartBeam System
HeartBeam (BEAT) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device Designation, BDD, for the HeartBeam System as a tool for assessing potential heart attacks a...
HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment.
HeartBeam downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded HeartBeam (BEAT) to Neutral from Buy without a price target The company issued a letter to shareholders describing its decision to not build a large commercial organization…
HeartBeam Slides: Investor presentation
HeartBeam has posted slides in relation to its latest quarterly earnings report, which was published on September 22, 2026.
HeartBeam says redirecting resources to myocardial infarction detection
HeartBeam (BEAT) issued a letter to shareholders from its Executive Chairman Richard Ferrari, and President and Founder, Branislav Vajdic, PhD, which read, in part, “HeartBeam is at an inflection poin...
HeartBeam, Inc. Letter to Shareholders
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. Letter to Shareholders.